gms | German Medical Science

Kongress Medizin und Gesellschaft 2007

17. bis 21.09.2007, Augsburg

Screening in the Era of HPV Vaccination

Meeting Abstract

Search Medline for

  • Mark Schiffman - DCEG, NCI, NIH, Bethesda, MD, USA

Kongress Medizin und Gesellschaft 2007. Augsburg, 17.-21.09.2007. Düsseldorf: German Medical Science GMS Publishing House; 2007. Doc07gmds350

The electronic version of this article is the complete one and can be found online at:

Published: September 6, 2007

© 2007 Schiffman.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



There is justifiable excitement about the recent introduction of prophylactic vaccines against human papillomavirus (HPV) types 16 (HPV-16) and HPV-18. Preventing these infections theoretically could avert the majority of cervical cancer cases worldwide. Numerous influential advocates are calling for universal vaccination of adolescent females. Given the promise of the vaccines, perhaps it is inevitable that vaccine introduction is proceeding before full consideration of how universal vaccination would affect existing, successful cervical cancer prevention programs. Determining the impact and cost effectiveness of the vaccines unavoidably will require time. Nevertheless, it is already clear that successful vaccination will dramatically reduce the effectiveness of screening methods including cytology, colposcopy, and HPV DNA testing. This is true because HPV16 causes the most evident screen-detectable precancerous abnormalities. Drawing from on simulations and actual post-vaccination trial data, this presentation will demonstrate the impact of HPV vaccination on screening. The obvious conclusion is that health planners considering the introduction of HPV vaccination must consider all aspects of cervical cancer prevention together, with full consideration of population effectiveness data. In particular, broad population immunity against HPV16 might even force a reconsideration of the utility of cytology and colposcopy, and accelerate the use of type-specific HPV testing or other molecular markers.


Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer. 2007;111:145-53.